课题基金 / 基金详情

EFFECT OF GLYCERYL TRIERUCATE THERAPY OF ALD

EFFECT OF GLYCERYL TRIERUCATE THERAPY OF ALD
三芥酸甘油酯治疗酒精性肝病的效果
批准号:
7378950
负责人:
HUGO W MOSER
金额:
$0.04万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-12-01 至 2006-11-30

项目摘要

项目成果

HUGO W MOSER的其他基金

相似基金

相关文献

中文摘要
翻译
该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者(PI)可能从另一个NIH来源获得了主要资金,因此可以在其他CRISP条目中表示。所列机构为中心机构,不一定是研究者机构。X连锁肾上腺脑白质营养不良(X-ALD)主要影响神经系统白色物质和肾上腺。它表现出广泛的表型表达。儿童大脑型最常见于6-8岁,并且进展迅速,通常在10岁之前导致严重的神经功能障碍。其他形式,如肾上腺髓质神经病(AMN)表现在成年期和进展较慢。主要的生化异常是饱和极长链脂肪酸(VLCFA)的积累,由于这些物质的过氧化物酶体氧化缺陷。很可能,但未证实,VLCFA过量有助于发病机制。1989年,研究表明,口服三油酸甘油酯和三芥酸甘油酯的4:1混合物(也称为Lorenzo Oil)可在4周内使血浆中VLCFA水平正常化。这一观察结果使人们希望向无症状患者施用这种物质可以降低随后神经损伤的频率和严重程度。本研究旨在评估情况是否如此。由于疾病的严重性,以及Lorenzo Oil对血浆VLCFA水平的显著生化作用,采用了非随机研究设计。临床疗效评价将基于无症状时接受油疗法的患者与历史对照组的临床病程比较。对美国和欧洲大量历史对照的发病年龄分析表明,31%至39%的生化缺陷患者在11岁时出现神经系统症状。本研究重点关注美国125名接受Lorenzo Oil治疗的神经学X-ALD患者的临床结局,并与欧洲涉及类似数量患者的类似研究密切协调。研究的主要重点将是在6岁之前开始这种治疗的患者,以及随访至11岁生日及以后的患者。我们预计将有50至60名患者符合这些标准。终点将是这些患者在11岁生日之前出现神经系统症状的比例。阳性结果将是显著低于31 - 39%的比例。功效计算表明,该样本量将允许在0.05显著性水平下检测到11岁时神经系统受累减少50%,功效为80%。
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. X-linked adrenoleukodystrophy (X-ALD) affects mainly the nervous system white matter and the adrenal gland. It shows a wide range of phenotypic expression. The childhood cerebral form manifests most commonly at 6-8 years of age, and is rapidly progressive, often leading to severe neurological disability before age 10 years. Other forms such as adrenomyloneuropathy (AMN) manifest in adulthood and progress more slowly. The principal biochemical abnormality is the accumulation of saturated very long chain fatty acids (VLCFA), due to a defect in the peroxisomal oxidation of these substances. It is likely, but not proven, that the VLCFA excess contributes to pathogenesis. In 1989 it was shown that the oral administration of a 4:1 mixture of glyceryl trioleate and glyceryl trierucate, also referred to as Lorenzo Oil, can normalize the levels of VLCFA in plasma within 4 weeks. This observation led to the hope administration of this substance to asymptomatic patients could reduce the frequency and severity of subsequent neurologic damage. The present study is designed to assess whether this is the case. Because of the severe nature of the disease, and the striking biochemical effect of Lorenzo Oil on plasma VLCFA levels, a non-randomized study design was adopted. Evaluation of clinical efficacy will be based upon the comparison of clinical course of patients who were placed on oil therapy while they were asymptomatic, with that in a historical control group. Analysis of the age of onset in a large series of historical controls in the US and in Europe, indicate that 31 to 39% of patients with the biochemical defect develop neurologic symptoms by eleven years of age. The present study focuses on the clinical outcome of 125 neurologically X-ALD patients in the US who have been placed on Lorenzo Oil therapy, and is coordinated closely with a similar study in Europe that involves a similar number of patients. The main focus of the study will be on patients who began this therapy before 6 years of age and who have been followed to and beyond their eleventh birthday. We anticipate that between 50 and 60 patients will meet these criteria. The end point will be the proportion of these patients who devleop neurologic symptoms prior to their eleventh birthday. A positive result would be a proportion which is significantly less than 31 to 39%. Power calculations indicate that this sample size will permit detection of a 50% reduction in neurologic involvement by eleven years of age at the 0.05 significance level with 80% power.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
X-LINKED ADRENOLEUKODYSTROPHY
PLACEBO-CONTROLLED STUDY OF X-ALD DIET THERAPY
  • 批准号:
    7604721
  • 项目类别:
  • 资助金额:
    $0.35万
  • 财政年份:
    2006
  • 负责人:
    HUGO W MOSER
  • 依托单位:
INTERNET MULTICENTER THERAPEUTIC TRIALS OF X LINKED ADRENOLEUKODYSTROPHY
THERAPEUTIC TRIALS OF X-LINKED ALD: PHASE III; LORENZO*
海外基金